Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 1941-1946, September 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mclntire, K. R.
Right arrow Articles by Patel, I. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mclntire, K. R.
Right arrow Articles by Patel, I. R.

Serum {alpha}-Fetoprotein as a Biochemical Marker for Hepatocellular Carcinoma1

K. Robert Mclntire2, Charles L. Vogel, Gerald L. Princler and Ila R. Patel

Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, Maryland 20014 [K. R. M., G. L. P.], and Solid Tumor Center, Uganda Cancer Institute, Kampala, Uganda [C. L. V., L. R. P.]

The demonstration of {alpha}-fetoprotein ({alpha}FP) has proven value in the diagnosis of hepatocellular carcinoma, but little is known of the dynamics of this protein during the course of the disease. A sensitive, quantitative test has been used to measure {alpha}FP serum levels in 90 Ugandan patients with histologically proven hepatocellular carcinoma. By the standard double diffusion immunological test, 71% of the patients were {alpha}FP positive. The quantitative values were spread over a wide range from 0.5 to 4000 µg/ml, with a median value of 71 µg/ml.

Forty-one patients (26 before treatment and 15 during chemotherapy) were followed with serial serum {alpha}FP determinations. There was a remarkable stability in the level for each patient, which levels showed little fluctuation during the time they were followed, regardless of the initial level. The only consistent change was a slight tendency for the serum {alpha}FP to rise as the disease progressed. A striking difference was noted in four patients receiving partial hepatectomy who showed a rapid decline in serum {alpha}FP and became negative postoperatively.

1 This work was supported in part by Contract PH 43-67-1343 from the National Cancer Institute, Bethesda, Md., and was presented in part at the Second Conference and Workshop on Embryonic and Fetal Antigens in Cancer, Oak Ridge, Tenn., February 14 to 16, 1972.

2 To whom reprint requests should be sent.

Received 4/ 5/72. Accepted 6/ 1/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.